trial
as of 2026-07-01A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
NCTId NCT00208156
at a glance
Phase 3 · Completed
Enrollment 87 (actual)
Sponsored by Corcept Therapeutics
Primary completion 2006-11
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
87 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2005-05
Primary completion
2006-11
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
Corcept TherapeuticsLead Sponsor
Investigators
1
Katherine Beebe, PhDStudy Director
Sites
13 total
San Diego, United StatesAtlanta, United StatesLas Vegas, United StatesClementon, United StatesNewark, United StatesToms River, United StatesGlen Oaks, United StatesLawrence, United StatesOklahoma City, United StatesPhiladelphia, United StatesBellaire, United StatesRichmond, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
87
Phase
PHASE3
Primary Completion Date
2006-11
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person